This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Heptares Achieves First Research Milestone In Research Collaboration With Cubist

WELWYN GARDEN CITY, England and BOSTON, July 22, 2013 /PRNewswire/ --

StaR® Generated to Important GPCR Target Selected by Cubist

Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved the first research milestone in its collaboration with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), which was announced in January 2013. The milestone is based on the generation of a stabilised (StaR®) form of a GPCR target selected by Cubist, a key step that will enable the structure of the target to be elucidated and a full structure-based drug design (SBDD) programme to be launched.

Cubist will make an undisclosed payment to Heptares as a result of this research milestone being achieved. Under the terms of the agreement, the collaboration is focusing on up to two GPCR drug targets to be selected by Cubist. Heptares has already received US$5.5 million upfront for the first target, and is eligible to receive up to approximately US$4 million in research funding plus milestones and royalties. Cubist also has the option to nominate a second GPCR target at a later point in the collaboration, which Heptares has agreed to work on according to pre-determined financials. Further terms of the agreement are not disclosed.

To date, Heptares has achieved all scientific milestones in its collaborations on or ahead of schedule, highlighting the power of its GPCR-focused platform. The structural information that Heptares can routinely access for a range of validated drug targets is being used to advance SBDD programmes and to develop lead candidates in multiple disease indications both in house and with partners.

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Morphosys, Takeda and Cubist, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

About G protein-coupled receptors (GPCRs)

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,328.04 +62.05 0.36%
S&P 500 2,017.97 +6.61 0.33%
NASDAQ 4,607.4410 +14.0160 0.31%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs